VANCOUVER, BC (Nov 10, 2021) - Segra International Corp. ("Segra"), an agriculture technology company and Titi Medical ("TiTi"), a leading South African medical cannabis producer, are pleased to announce the execution of a Nursery Provision Agreement.
Under the terms of the royalty-based agreement, Segra will supply TiTi with premium cannabis cultivars for propagation and distribution to other licensed growers within the regions of South Africa and Lesotho. These premium cultivars will be provided to TiTi in the form of clean-stock tissue culture plantlets. The plantlets will then be grown into mother stock plants to produce cuttings that TiTi will distribute to other licenced growers in the region.
The first shipment under this collaboration, one of the largest ever to South Africa, consisted of 8 unique cannabis cultivars and arrived at TiTi's facility in late September 2021. These plantlets are currently being propagated and prepared for distribution within the next quarter, enabling cultivators in South Africa and Lesotho to access Segra cultivars for production use. This Nursery Provision Agreement will help TiTi to significantly de-risk their operations through ongoing refreshments of clean stock propagation material to enhance plant health and reduce pathogen risks in the nursery environment.
Ambassador Wadih Chammas, Founder of TiTi Medical, commented, "We are pleased to build upon our existing relationship with Segra as we prepare to expand into the cannabis nursery business. Segra's high-performance cannabis genetics combined with our state-of-the-art cannabis nursery facility will allow us to support the success of numerous licenced growers in our region through the large-scale provision of cannabis clones and young plants."
"To date, cultivators in many regions such as South Africa have had limited access to high-value cannabis cultivars with strong agronomic performance due to a lack of genetic availability within the local legal market," said Jamie Blundell, Segra's Chief Executive Officer. "This distribution partnership will allow both TiTi and other cannabis cultivators in the region to leverage the high performing cultivars in Segra's portfolio and drive agronomic efficiencies, resulting in a supply of premium cannabis products to the booming domestic and international cannabis markets."
To learn more about Segra's Nursery Provision programs, contact growth@segra-intl.com
About Segra International:
Segra is an agriculture technology company offering plant tissue culture, plant genomics, and pathogen detection services to accelerate the advancement of the cannabis industry. Its proprietary technologies empower its clients to drive financial performance and mitigate risk while exploring the next frontier of optimized cultivation practices for the rapidly evolving cannabis consumer. Segra has developed industrial-scale laboratories to produce Verified Segra Stock™, robust, and DNA-fingerprinted cannabis plantlets for licensed producers globally. Segra has assembled a world-class team of specialists in agronomy, molecular genetics, plant tissue culture, and regulatory compliance to support this vision. Learn more at segra-intl.com or view the 2021 Cultivar and Services Catalogue.
About TiTi Medical:
TiTi Medical is a premium cannabis producer based out of South Africa. With both greenhouse and indoor cultivation facilities, TiTi can produce high-quality cannabis at scale to serve domestic and international markets. Learn more at www.titimedical.com.
Contact For Further Information
Forward-Looking Information
This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
COPYRIGHT 2024
